The MOPETT Trial took sub-massive PE patients and randomized them to half-dose tPA vs. standard care. No bleeds in either group. 41% ARR of pulmonary hypertension at 28 months.
Study Description from the Author
Does this change your game?
A new trial using a similar protocol showed benefit without complications (Clinical Cardiology Volume 37, Issue 2, pages 78–82, February 2014)
Latest posts by Scott Weingart (see all)
- EMCrit Podcast 199 – Management of Massive Hemoptysis with Oren Friedman - May 14, 2017
- Podcast 198 – Insulin Pumps and Such with Josh Miller, MD - May 1, 2017
- Ketamine ……. then Rocuronium, DSI & The Timing Principle - April 25, 2017